How to assess liver fibrosis in chronic hepatitis C: serum markers or transient elastography vs. liver biopsy?
- PMID: 21205132
- DOI: 10.1111/j.1478-3231.2010.02380.x
How to assess liver fibrosis in chronic hepatitis C: serum markers or transient elastography vs. liver biopsy?
Abstract
The assessment of liver fibrosis is a major issue in the management of patients with chronic hepatitis C. Liver biopsy has traditionally been considered the gold standard for the evaluation of tissue damage, including fibrosis. In addition, it detects associated lesions such as steatosis, steatohepatitis or iron overload, which provide useful information for patient management and prognosis. Liver biopsy is, however, an invasive procedure, with a risk of rare but potentially life-threatening complications and it is prone to sampling errors. These limitations have led to the development of non-invasive methods. Currently available tests rely on two different but complementary approaches: (i) a 'biological' approach based on the dosage of serum biomarkers of fibrosis; (ii) a 'physical' approach based on the measurement of liver stiffness, using transient elastography. Although significant progress has been made in the non-invasive diagnosis of fibrosis, it is increasingly clear that these methods will not completely replace liver biopsy. Instead, non-invasive methods and liver biopsy should be used in an integrated approach for more efficient and convenient management of patients with chronic hepatitis C. The aim of this review is to discuss the advantages and limitations of liver biopsy and non-invasive methods and the perspectives for their use in clinical practice.
© 2011 John Wiley & Sons A/S.
Similar articles
-
Invasive and non-invasive methods for the assessment of fibrosis and disease progression in chronic liver disease.Best Pract Res Clin Gastroenterol. 2011 Apr;25(2):291-303. doi: 10.1016/j.bpg.2011.02.003. Best Pract Res Clin Gastroenterol. 2011. PMID: 21497746 Review.
-
Assessing liver fibrosis.Expert Rev Gastroenterol Hepatol. 2008 Aug;2(4):541-52. doi: 10.1586/17474124.2.4.541. Expert Rev Gastroenterol Hepatol. 2008. PMID: 19072402 Review.
-
Transient elastography and other noninvasive tests to assess hepatic fibrosis in patients with viral hepatitis.J Viral Hepat. 2009 May;16(5):300-14. doi: 10.1111/j.1365-2893.2009.01087.x. Epub 2009 Feb 25. J Viral Hepat. 2009. PMID: 19254351 Review.
-
Noninvasive methods to assess liver disease in patients with hepatitis B or C.Gastroenterology. 2012 May;142(6):1293-1302.e4. doi: 10.1053/j.gastro.2012.02.017. Gastroenterology. 2012. PMID: 22537436 Review.
-
Assessment of hepatitis C: non-invasive fibrosis markers and/or liver biopsy.Liver Int. 2009 Jan;29 Suppl 1:19-22. doi: 10.1111/j.1478-3231.2008.01940.x. Liver Int. 2009. PMID: 19207962 Review.
Cited by
-
Novel non-invasive biological predictive index for liver fibrosis in hepatitis C virus genotype 4 patients.World J Hepatol. 2016 Nov 18;8(32):1392-1401. doi: 10.4254/wjh.v8.i32.1392. World J Hepatol. 2016. PMID: 27917265 Free PMC article.
-
Effect of Hepatic Inflammation in Chronic Hepatitis C Infection on Fibrosis Assessment by Arrival Time Parametric Imaging.Ultrasound Q. 2018 Sep;34(3):128-132. doi: 10.1097/RUQ.0000000000000355. Ultrasound Q. 2018. PMID: 29634669 Free PMC article.
-
Chronic hepatitis C virus infection: Serum biomarkers in predicting liver damage.World J Gastroenterol. 2016 Jan 28;22(4):1367-81. doi: 10.3748/wjg.v22.i4.1367. World J Gastroenterol. 2016. PMID: 26819506 Free PMC article. Review.
-
Evaluation of liver fibrosis: "Something old, something new…".Ann Gastroenterol. 2016 Oct-Dec;29(4):445-453. doi: 10.20524/aog.2016.0046. Epub 2016 May 27. Ann Gastroenterol. 2016. PMID: 27708509 Free PMC article. Review.
-
Role of liver biopsy in the era of direct-acting antivirals.Curr Gastroenterol Rep. 2013 Feb;15(2):307. doi: 10.1007/s11894-012-0307-z. Curr Gastroenterol Rep. 2013. PMID: 23319086 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
